Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
Abstract Background The survival rate for patients with relapsed and refractory acute myeloid leukaemia (R/R-AML) remains poor, and treatment is challenging. Chimeric antigen receptor T cells (CAR-T cells) have been widely used for haematologic malignancies. Current CAR-T therapies for acute myeloid...
Main Authors: | Yu Lu, Ying Liu, Shupeng Wen, Na Kuang, Xuejun Zhang, Jianqiang Li, Fuxu Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-022-03797-7 |
Similar Items
-
Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
by: Riana van der Linde, et al.
Published: (2023-10-01) -
Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
by: Nikhil Patkar, et al.
Published: (2019-06-01) -
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01) -
Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
by: Caroline Dix, et al.
Published: (2020-06-01) -
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response
by: Hong Yuen Wong, et al.
Published: (2019-01-01)